麗珠醫藥(01513.HK)2021年度淨利預增0%至10%
格隆匯1月14日丨麗珠醫藥(01513.HK)發佈2021年度業績預吿,2021年1月1日至12月31日期間,預計歸屬於上市公司股東的淨利潤約人民幣17.149億元—人民幣18.864億元,比上年同期增長約0%—10%。預計歸屬於上市公司股東的扣除非經常性損益的淨利潤約人民幣15.747億元—人民幣17.179億元,比上年同期增長約10%—20%。
公吿稱,本年度公司化學制劑板塊銷售增速明顯,消化道、促性激素、精神等重點優勢領域銷售同比實現持續快速增長,加之原料藥板塊高端特色原料藥佔比及盈利穩步提升,保障了公司整體業績的穩步增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.